CFS
RYTM icon

Cannon Financial Strategists’s Rhythm Pharmaceuticals RYTM Stock Holding History

Cannon Financial Strategists’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.11M Hold
10,000
– – 0.13% 53
2026
Q1 		$870K Hold
10,000
– – 0.11% 56
2025
Q4 		$1.07M Hold
10,000
– – 0.15% 47
2025
Q3 		$1.01M Hold
10,000
– – 0.14% 48
2025
Q2 		$632K Hold
10,000
– – 0.1% 55
2025
Q1 		$530K Hold
10,000
– – 0.09% 59
2024
Q4 		$560K Buy
+10,000
New +$552K 0.1% 58

Other funds holding RYTM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Cannon Financial Strategists's RYTM Position: Q2 2026 in Review

Cannon Financial Strategists held its Rhythm Pharmaceuticals (RYTM) position steady in Q2 2026 at 10,000 shares worth $1.11M. The position accounts for 0.13% of the portfolio, ranked #53.

Cannon Financial Strategists first reported a position in RYTM in Q4 2024 and has held it in 7 quarters since. 90 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Cannon Financial Strategists held 10,000 shares of Rhythm Pharmaceuticals worth $1.11M as of Q2 2026.
  • Cannon Financial Strategists left its Rhythm Pharmaceuticals share count unchanged in Q2 2026.
  • Rhythm Pharmaceuticals made up 0.13% of Cannon Financial Strategists's portfolio in Q2 2026, its #53 holding.
  • Cannon Financial Strategists first reported a position in Rhythm Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • 90 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Cannon Financial Strategists's 13F filing for Q2 2026, filed 7 Aug 2026.